TAK in the 13F filings
Takeda Pharmaceutical Co Ltd · CUSIP 874060205
- Quarter end
- 30 Sep 2023
- the date the book describes
- Filed
- 14 Nov 2023
- latest of these filings; the earliest 13 Nov 2023
- Managers listing it
- 4
- at least, of 95 tracked, among listed positions
- Comparable managers
- 93
- filed both Q2 2023 and Q3 2023; 4 listed it in both
- Shares listed
- 20,071,686
- combined, among listed positions
- Reported value
- $311m
- combined, at the quarter end
Managers listing TAK in Q3 2023
4 of 4 holders
| Action | Filing | |||||
|---|---|---|---|---|---|---|
| Capital Research Global Investors | 13,794,359 | $213m | 0.06% | Added | +6,518 | 13 Nov 2023 (the filing on sec.gov) |
| Renaissance Technologies LLC | 3,230,900 | $50m | 0.09% | Trimmed | -419,100 | 14 Nov 2023 (the filing on sec.gov) |
| Arrowstreet Capital LP | 2,473,910 | $38m | under 0.1% | Added | +139,715 | 14 Nov 2023 (the filing on sec.gov) |
| Voloridge Investment Management LLC | 572,517 | $8.9m | under 0.1% | Trimmed | -9,149 | 14 Nov 2023 (the filing on sec.gov) |
Largest increases and reductions, by shares
Increases
- Arrowstreet Capital LPexisting position · 2,473,910 shares now+139,715
- Capital Research Global Investorsexisting position · 13,794,359 shares now+6,518
Reductions
- Renaissance Technologies LLCexisting position · 3,230,900 shares now-419,100
- Voloridge Investment Management LLCexisting position · 572,517 shares now-9,149
New positions and exits
New (0)
No new position among listed positions.
Exited (1)
- Point72 Asset Management LPwas $33m
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q4 2018 | 3 | $83m | n.a. | n.a. |
| Q1 2019 | 12 | $1.2bn | n.a. | n.a. |
| Q2 2019 | 6 | $721m | n.a. | n.a. |
| Q3 2019 | 9 | $718m | n.a. | n.a. |
| Q4 2019 | 6 | $645m | n.a. | n.a. |
| Q1 2020 | 4 | $362m | n.a. | n.a. |
| Q2 2020 | 4 | $395m | n.a. | n.a. |
| Q3 2020 | 4 | $423m | n.a. | n.a. |
| Q4 2020 | 5 | $549m | n.a. | n.a. |
| Q1 2021 | 4 | $699m | n.a. | n.a. |
| Q2 2021 | 4 | $476m | n.a. | n.a. |
| Q3 2021 | 4 | $410m | n.a. | n.a. |
| Q4 2021 | 2 | $111m | n.a. | n.a. |
| Q2 2022 | 3 | $69m | n.a. | n.a. |
| Q3 2022 | 3 | $68m | n.a. | n.a. |
| Q4 2022 | 5 | $208m | n.a. | n.a. |
| Q1 2023 | 5 | $349m | n.a. | n.a. |
| Q2 2023 | 5 | $353m | n.a. | n.a. |
| Q3 2023 | 4 | $311m | n.a. | n.a. |
| Q4 2023 | 5 | $374m | 4 | 1 |
| Q1 2024 | 3 | $228m | 0 | 2 |
| Q2 2024 | 4 | $243m | 3 | 1 |
| Q3 2024 | 3 | $236m | 2 | 1 |
| Q4 2024 | 3 | $271m | 1 | 2 |
| Q1 2025 | 3 | $256m | 3 | 0 |
| Q2 2025 | 2 | $257m | 2 | 0 |
| Q3 2025 | 2 | $253m | 2 | 0 |
| Q4 2025 | 4 | $355m | 11 | 8 |
| Q1 2026 | 3 | $467m | 13 | 7 |
| Q2 2026 | 3 | $410m | 13 | 10 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
TAK and LLY →TAK and JNJ →TAK and VRTX →Choose a stock to compare with TAK →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own TAK, latest filings →Back to the 13F Explorer →